Amphastar Pharmaceuticals
AMPH
104 hedge funds and large institutions have $363M invested in Amphastar Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 41 reducing their positions, and 12 closing their positions.
0.78% less ownership
Funds ownership: 44.7% → 43.92% (-0.78%)
4% less funds holding
Funds holding: 108 → 104 (-4)
20% less capital inflows, than outflows
Capital inflows: $12.5M | Capital outflows: $15.6M
24% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 41
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.72M |
| 2 |
BlackRock
New York
|
+$1.93M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$1.78M |
| 4 |
ACM
Argent Capital Management
St Louis,
Missouri
|
+$1.01M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$709K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.13M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.65M |
| 4 |
Morgan Stanley
New York
|
-$1.08M |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$989K |
AMPH Hedge Fund Activity: Q3 2017 in Review
104 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2017, worth a combined $363M — down 0.71% from $365M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AMPH and 8 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 31 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $3.72M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $3.13M sold.
- 104 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2017, down from 108 in Q2 2017.
- Funds reported $363M of Amphastar Pharmaceuticals stock for Q3 2017, down 0.71% quarter-over-quarter.
- 8 funds opened new Amphastar Pharmaceuticals positions in Q3 2017 and 12 closed out, a net change of -4 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2017 was Dimensional Fund Advisors, an estimated $3.72M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2017 was Point72 Asset Management, an estimated $3.13M sold.
Based on aggregated 13F filings for Q3 2017.